Support: 888-992-3836 Home NewsWire Subscriptions
InvestorsHub Logo
Login/Register
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Personalis Inc (PSNL)

  7. Personalis Inc (PSNL) Financials

PSNL

Personalis Inc
2.60
-0.11 (-4.06%)
Upgrade to Real-Time

Personalis Inc. (PSNL) Fundamentals
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.
SHARE INFORMATION
Market Cap$ 125,722,073
Shares Outstanding46,736,830
Float28,655,019
Percent Float61.31%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 65,047,000
Latest Fiscal EPS$ -2.48
Latest Fiscal Date2022-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions277
Institutional Holdings Date2023-02-28
Institutional Bought Previous 3 Months1,314,547
Institutional Holdings Percent111.0%
Institutional Sold Previous 3 Months6,050,975
Insider Holdings Date2023-02-28
Insider Bought Previous 3 Months20,000
Insider Holdings Percent3.1
Insider Sold Previous 3 Months48,006
Insider Shares Owned1,440,644
TRADING INFO
52 Week High$ 8.96
52 Week Low$ 1.73
52 Week High Change$ -68.83
21 Day Moving Average$ 2.8712
21 Day Extended Moving Average$ 2.8667
50 Day Moving Average$ 2.9081
50 Day Extended Moving Average$ 2.8535
200 Day Moving Average$ 3.1276
200 Day Extended Moving Average$ 4.1313
10 Day Average Volume357,193
20 Day Average Volume460,477
30 Day Average Volume450,054
50 Day Average Volume600,691
Alpha-0.042833
Beta1.4374
Standard Deviation0.189920
R20.181992
7 Day Price Change$ -0.07
7 Day Percent Change-2.54%
21 Day Price Change$ 0.07
21 Day Percent Change2.67%
30 Day Price Change$ -0.49
30 Day Percent Change-15.41%
Month to Date Price Change$ -0.32
Month to Date Percent Change-10.63%
Quarter to Date Price Change$ 0.71
Quarter to Date Percent Change35.86%
180 Day Price Change$ -0.39
180 Day Percent Change-12.66%
200 Day Price Change$ -0.51
200 Day Percent Change-15.94%
Year to Date Price Change$ 0.71
Year to Date Percent Change35.86%

Personalis Inc. (PSNL) Key Ratios

PROFITABILITY
EBIT Margin-148.1%
EBITDA Margin-137.9%
Pre-Tax Profit Margin-83.1%
Profit Margin Count-81.53%
Gross Margin20.5%
Profit Margin TOT-81.53%
INCOME STATEMENTS
Revenue$ 65,047,000
Revenue Per Share$ 1.3918
Revenue (3 Years)$ 0.76
Revenue (5 Years)$ 15.93
FINANCIAL STRENGTH
Price to Tangible Book0.60
Total Debt To Equity0.20
Int Coverage-562.60
Current Ratio6.00
Leverage Ratio1.30
Quick Ratio5.60
Long Term Debt To Capital0.16
VALUATION MEASURES
PE Ratio64.40
Enterprise Value$ 10,920,387
Price to Sales1.9328
Price to Free Cash-1.10
PE High Last 5 Years0.00
Price To Book0.60
Price To Cash Flow103.80
PE Low Last 5 Years0.00
Price to Tangible Book0.60
MANAGEMENT EFFECTIVENESS
Receivables Turnover3.60
Invoice Turnover10.10
Assets Turnover0.20
Return Assets-33.99
Return on Equity-44.36
Return on Capital-30.49

Personalis Inc. (PSNL) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorDeloitte & Touche LLP
CEOChristopher Hall
Emplyoees399
Last AuditUQ
CIK0001527753
IndustryMedical Diagnostics & Research
SectorHealthcare
NAICSIn-Vitro Diagnostic Substance Manufacturing(325413)
CONTACT INFO
Address6600 Dumbarton Circle
Fremont, CA 94555
Websitehttps://www.personalis.com
Facsimile+1 650 752-1301
Telephone+1 650 752-1300
Email-


Your Recent History
NASDAQ
PSNL
Personalis
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.